Literature DB >> 28487550

Liver cancer: Nivolumab: checkmate for hepatocellular carcinoma?

Katrina Ray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28487550     DOI： 10.1038/nrgastro.2017.62

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321
  1 in total
  1 in total

1.  A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma.

Authors:  Yiming Lu; Aiqing Yang; Cheng Quan; Yingwei Pan; Haoyun Zhang; Yuanfeng Li; Chengming Gao; Hao Lu; Xueting Wang; Pengbo Cao; Hongxia Chen; Shichun Lu; Gangqiao Zhou
Journal:  Nat Commun       Date:  2022-08-06       Impact factor: 17.694
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.